399 related articles for article (PubMed ID: 18338894)
1. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP
J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894
[TBL] [Abstract][Full Text] [Related]
2. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Tsantrizos YS
Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
[TBL] [Abstract][Full Text] [Related]
3. Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement.
Di Francesco ME; Dessole G; Nizi E; Pace P; Koch U; Fiore F; Pesci S; Di Muzio J; Monteagudo E; Rowley M; Summa V
J Med Chem; 2009 Nov; 52(22):7014-28. PubMed ID: 19856919
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V
Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390
[TBL] [Abstract][Full Text] [Related]
5. P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease.
Arasappan A; Njoroge FG; Chen KX; Venkatraman S; Parekh TN; Gu H; Pichardo J; Butkiewicz N; Prongay A; Madison V; Girijavallabhan V
Bioorg Med Chem Lett; 2006 Aug; 16(15):3960-5. PubMed ID: 16730985
[TBL] [Abstract][Full Text] [Related]
6. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
[TBL] [Abstract][Full Text] [Related]
7. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.
Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B
Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
Perni RB; Pitlik J; Britt SD; Court JJ; Courtney LF; Deininger DD; Farmer LJ; Gates CA; Harbeson SL; Levin RB; Lin C; Lin K; Moon YC; Luong YP; O'Malley ET; Rao BG; Thomson JA; Tung RD; Van Drie JH; Wei Y
Bioorg Med Chem Lett; 2004 Mar; 14(6):1441-6. PubMed ID: 15006379
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
Ding CZ; Zhang YK; Li X; Liu Y; Zhang S; Zhou Y; Plattner JJ; Baker SJ; Liu L; Duan M; Jarvest RL; Ji J; Kazmierski WM; Tallant MD; Wright LL; Smith GK; Crosby RM; Wang AA; Ni ZJ; Zou W; Wright J
Bioorg Med Chem Lett; 2010 Dec; 20(24):7317-22. PubMed ID: 21067923
[TBL] [Abstract][Full Text] [Related]
11. Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320.
Parsy CC; Alexandre FR; Bidau V; Bonnaterre F; Brandt G; Caillet C; Cappelle S; Chaves D; Convard T; Derock M; Gloux D; Griffon Y; Lallos LB; Leroy F; Liuzzi M; Loi AG; Moulat L; Chiara M; Rahali H; Roques V; Rosinovsky E; Savin S; Seifer M; Standring D; Surleraux D
Bioorg Med Chem Lett; 2015 Nov; 25(22):5427-36. PubMed ID: 26410074
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease.
Chen KX; Njoroge FG; Pichardo J; Prongay A; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
J Med Chem; 2005 Oct; 48(20):6229-35. PubMed ID: 16190750
[TBL] [Abstract][Full Text] [Related]
13. Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
Bogen SL; Pan W; Ruan S; Nair LG; Arasappan A; Bennett F; Chen KX; Jao E; Venkatraman S; Vibulbhan B; Liu R; Cheng KC; Guo Z; Tong X; Saksena AK; Girijavallabhan V; Njoroge FG
J Med Chem; 2009 Jun; 52(12):3679-88. PubMed ID: 19456105
[TBL] [Abstract][Full Text] [Related]
14. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
[TBL] [Abstract][Full Text] [Related]
15. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.
Raboisson P; Lin TI; Kock Hd; Vendeville S; Vreken WV; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Surleraux D; Wigerinck P; Nilsson M; Rosenquist S; Samuelsson B; Simmen K
Bioorg Med Chem Lett; 2008 Sep; 18(18):5095-100. PubMed ID: 18722116
[TBL] [Abstract][Full Text] [Related]
17. Molecular modeling based approach, synthesis and in vitro assay to new indole inhibitors of hepatitis C NS3/4A serine protease.
Ismail NS; Hattori M
Bioorg Med Chem; 2011 Jan; 19(1):374-83. PubMed ID: 21138791
[TBL] [Abstract][Full Text] [Related]
18. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells.
Hamill P; Jean F
Biochemistry; 2005 May; 44(17):6586-96. PubMed ID: 15850392
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.
Vendeville S; Nilsson M; de Kock H; Lin TI; Antonov D; Classon B; Ayesa S; Ivanov V; Johansson PO; Kahnberg P; Eneroth A; Wikstrom K; Vrang L; Edlund M; Lindström S; Van de Vreken W; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Van Dooren M; Kindermans N; Surleraux D; Wigerinck P; Rosenquist A; Samuelsson B; Simmen K; Raboisson P
Bioorg Med Chem Lett; 2008 Dec; 18(23):6189-93. PubMed ID: 18954982
[TBL] [Abstract][Full Text] [Related]
20. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease.
Sheng XC; Appleby T; Butler T; Cai R; Chen X; Cho A; Clarke MO; Cottell J; Delaney WE; Doerffler E; Link J; Ji M; Pakdaman R; Pyun HJ; Wu Q; Xu J; Kim CU
Bioorg Med Chem Lett; 2012 Apr; 22(7):2629-34. PubMed ID: 22366653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
